Procter & Gamble Health Ltd (PGHL)
₹6,714.00
Mkt cap
₹11,145 Cr
P/E ratio
34.10
P/B
21.25
Div yield
2.31%
ROE
61.60%
ROCE
83.50%
EPS (TTM)
₹196.89
Book value
₹316
52W range
4,779–6,919
Sector
Healthcare
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. [1]
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthLow
TechnicalsBullish
52-week range
−2.96% from high₹6,714
₹4,779+40.50% from low₹6,919
Current
₹6,714.00
Prev close
₹6,745.00
Day
−0.46%
Price performance
1D
−0.46%
1W
−2.02%
1M
+7.73%
3M
+30.66%
6M
+23.18%
1Y
+14.30%
YTD
+17.76%
Financials
FRevenue, profit & margin
P/E ratio
34.1×
PGHL is 0% above the sector median of 34.0×
PGHL34.1×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 321 | 301 | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 | |
| Expenses | 241 | 256 | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 | |
| Operating Profit | 80 | 45 | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 | 110 | 136 | |
| OPM % | 25% | 15% | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% | 30% | 37% | |
| Other Income | 5 | 5 | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 | 4 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 6 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | |
| Profit before tax | 79 | 44 | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 | 133 | |
| Tax % | 25% | 32% | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% | 29% | 29% | |
| Net Profit | 59 | 30 | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 | 95 | |
| EPS in Rs | 35.66 | 17.96 | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
6 Aug '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202651.82%Promoter
Promoters51.82%
FIIs6.33%0.13
DIIs12.44%1.23
Public29.41%1.11
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| P & G Health Ltd | ₹6,714.00 | 34.09 | 11,145 | 2.31% | 95 | +54.63% | 370 | +19.12% | 83.53% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2013nseFinancial Year 2012bse
Concall transcripts6
Credit ratings5
Announcements5
Update Regarding Company'S Annual General Meeting For The Financial Year 2025-26 And Record Date 15 Jul - 59th AGM on September 3, 2026; record date August 27, 2026; dividend payment by September 27, 2026.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 3 Jul - Dear Sir, Please find attached signed certificate for confirming compliance under Regulation 74 (5) of the SEBI (DP) Regulations, for the quarter ended June 30, …Communication In Respect Of Deduction Of Tax At Source (TDS) On The Amount Of Dividend Income From Procter & Gamble Health Limited ('The Company') 26 Jun - Board recommended final dividend of Rs.45 per share for FY2025-26; TDS documents due by August 12, 2026.Closure of Trading Window 26 JunBoard Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On August 6, 2026 26 Jun - Board meeting on August 6, 2026 to approve Q1 FY2027 unaudited financial results.